63514-63-6

Usage

Uses

Used in Organic Synthesis:
N-[4-(2-bromopropanoyl)phenyl]acetamide is utilized as a reagent in organic synthesis for its ability to react with a variety of nucleophiles. This property allows it to be a versatile intermediate in the preparation of a range of organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, N-[4-(2-bromopropanoyl)phenyl]acetamide serves as an important building block. Its stability and reactivity make it suitable for the development of new pharmaceutical agents, potentially leading to the creation of novel drugs with improved therapeutic profiles.
Overall, N-[4-(2-bromopropanoyl)phenyl]acetamide is a key component in the fields of organic chemistry and pharmaceuticals, contributing to the advancement of chemical synthesis and drug discovery.

InChI:InChI=1/C11H12BrNO2/c1-7(12)11(15)9-3-5-10(6-4-9)13-8(2)14/h3-7H,1-2H3,(H,13,14)

Upstream product

• 563-76-8 α-bromopropionyl bromide 
• 103-84-4 Acetanilid 
• 7148-74-5 2-Bromopropionyl chloride 
• 62-53-3 aniline 
• 70-69-9 1-(4-aminophenyl)-1-propanone 
• 16960-49-9 N-(4-propionylphenyl)acetamide 

Downstream Products

• 1037019-96-7 C₂₃H₂₈N₂O₂ 
• 104657-22-9 (+/-)-2-(N-tert-butylamino)-4'-aminopropiophenone 
• 97110-67-3 1-(4-acetylaminophenyl)-2-tert.-butylaminopropanone 
• 136609-85-3 6-(3,4-diaminophenyl)-5-methyl-2,3,4,5-tetrahydropyridazin-3-one 
• 36725-28-7 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone 
• 36725-28-7 OR-1855 
• 1221499-65-5 (R)-(-)-6-[4-(2-furanylmethylene)amino]phenyl-5-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 1221499-63-3 (R)-(-)-6-[4-(2-pyridinylmethylene)amino]phenyl-5-methyl-4,5-dihydro-3(2H)-pyridazinone 
• 1221499-62-2 C₁₈H₁₅Cl₂N₃O 
• 1221499-61-1 C₂₁H₂₃N₃O₄ 
• 1221499-60-0 C₁₈H₁₆ClN₃O 
• 1221499-59-7 C₁₈H₁₇N₃O₂ 
• 1221499-58-6 C₁₈H₁₇N₃O₂ 
• 1221499-57-5 C₁₈H₁₇N₃O₃ 

Relevant academic research and scientific papers

Optimizing Water Exchange Rates and Rotational Mobility for High-Relaxivity of a Novel Gd-DO3A Derivative Complex Conjugated to Inulin as Macromolecular Contrast Agents for MRI

Thanks to the understanding of the relationships between the residence lifetime τM of the coordinated water molecules to macrocyclic Gd-complexes and the rotational mobility τR of these structures, and according to the theory for paramagnetic relaxation, it is now possible to design macromolecular contrast agents with enhanced relaxivities by optimizing these two parameters through ligand structural modification. We succeeded in accelerating the water exchange rate by inducing steric compression around the water binding site, and by removing the amide function from the DOTA-AA ligand [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(p-aminoanilide)] (L) previously designed. This new ligand 10[2(1-oxo-1-p-propylthioureidophenylpropyl]-1,4,7,10-tetraazacyclodecane-1,4,7-tetraacetic acid (L1) was then covalently conjugated to API [O-(aminopropyl)inulin] to get the complex API-(GdL1)x with intent to slow down the rotational correlation time (τR) of the macromolecular complex. The evaluation of the longitudinal relaxivity at different magnetic fields and the study of the 17O-NMR at variable temperature of the low-molecular-weight compound (GdL1) showed a slight decrease of the τM value (τM310 =?331?ns vs. τM310 =?450?ns for the GdL complex). Consequently to the increase of the size of the API-(GdL1)x complex, the rotational correlation time becomes about 360 times longer compared to the monomeric GdL1 complex (τR?=?33,700?ps), which results in an enhanced proton relaxivity.

Preparation method of key intermediate of Pimobendan

The invention discloses a preparation method of a key intermediate of Pimobendan. The method comprises steps as follows: (i) a compound I is synthesized; (ii) the compound I is subjected to nucleophilic substitution, and a compound II is produced; (iii) t

(±)-2-(N-tert-Butylamino)-3′-[125I]-iodo-4′- azidopropiophenone: A dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban)

Towards addressing the knowledge gap of how bupropion interacts with the dopamine transporter (DAT) and nicotinic acetylcholine receptors (nAChRs), a ligand was synthesized in which the chlorine of bupropion was isosterically replaced with an iodine and a photoreactive azide was added to the 4′-position of the aromatic ring. Analog (±)-3 (SADU-3-72) demonstrated modest DAT and α4β2 nAChR affinity. A radioiodinated version was shown to bind covalently to hDAT expressed in cultured cells and affinity-purified, lipid-reincorporated human α4β2 neuronal nAChRs. Co-incubation of (±)-[125I]-3 with non-radioactive (±)-bupropion or (-)-cocaine blocked labeling of these proteins. Compound (±)-[125I]-3 represents the first successful example of a DAT and nAChR photoaffinity ligand based on the bupropion scaffold. Such ligands are expected to assist in mapping bupropion-binding pockets within plasma membrane monoamine transporters and ligand-gated nAChR ion channels.

Substituted Phenylpiperazinyl Aralkylalcohol Derivatives, Pharmaceutical Compositions Containing Such Derivatives and Uses Thereof

The invention relates to a substituted phenylpiperazine aryl alkanol derivative represented by the following general formula and its salt and hydrate, wherein C1 and C2 represent chiral carbon atoms, and the compound is one of the six isomers: (1RS, 2SR), (1RS, 2RS), (1R, 2S), (1S, 2S), (1R, 2R) or (1S, 2R); and R, R1, R2, R3 and Ar are as defined in the specification. The derivative is non-opioid analgesic, has good analgesic effect and relatively small side effects. The invention also relates to a composition comprising the derivative and its use.

Synthesis and anti-congestive heart failure activity of novel levosimendan analogues

A series of levosimendan analogues were designed and synthesized, employing the Friedel-Crafts reaction, hydrolysis, and cyclization from the key intermediate compound R(-)-6-(4-aminophenyl)-5-methyl-4, 5-dihydro-3(2H)- pyridazinone, which was obtained from the starting material, acetanilide. These compounds, except 1b, exhibited potent anti-congestive heart failure activities, especially the compounds 1e and 1k, which showed more effective action than levosimendan. Springer Science+Business Media, LLC 2010.

Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors

To prepare thiol-reactive ifenprodil derivatives designed as potential probes for cysteine-substituted NR2B containing NMDA receptors, electrophilic centers were introduced in different areas of the ifenprodil structure. Intermediates and final compounds were evaluated by binding studies and by electrophysiology to determine the structural requirements for their selectivity. The reactive compounds were further tested for their stability and for their reactivity in model reactions; some were found suitable as structural probes to investigate the binding site and the docking mode of ifenprodil in the NR2B subunit.

Synthesis and bioactivity of 6-phenyl-4,5-dihydro-3(2H)-pyridazinone derivatives

A series of 6-phenyl-4,5-dihydro-3(2H)-pyridazinone derivatives was prepared and examined for cardiotonic activity. The structures of these new pyridazinone derivatives were confirmed by IR, 1H-NMR and mass spectrum. The cardiotonic activities of these compounds were studied on isolated perfused toad heart and compared with the activity of levosimendan (CAS 141505-33-1). Compound 5a emerged as the most interesting compound in this series with potential cardiotonic activity. ECV Editio Cantor Verlag.

Chemical process

This invention relates to a Friedel-Crafts acylation process using trichlorobenzene as solvent.